DJIA 17,928.20 -142.20 -0.79%
NASDAQ 4,939.33 -77.60 -1.55%
S&P 500 2,089.46 -25.03 -1.18%
market minute promo

15.12 -0.57 (-3.63%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

HALO $15.12 -3.63%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $15.63
Previous Close $15.69
Daily Range $15.00 - $15.71
52-Week Range $6.95 - $17.27
Market Cap $1.9B
P/E Ratio -28.02
Dividend (Yield) $0.00 (0.0%)
Volume 1,320,789
Average Daily Volume 1,283,970
Current FY EPS -$0.45

Sector

Healthcare

Industry

Drug Makers

Halozyme Therapeutics, Inc. (HALO) Description

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets. Website: http://www.halozyme.com/

News & Commentary Rss Feed

Can Pfizer’s Cholesterol Drug Catch Up To The Competition?

Pfizer’s bococizumab remains in last place in the PCSK9 race. Will it arrive too late to make a meaningful impact on the market?

2 Small Biotech Stocks In Full Breakout Mode

Two Small Biotech Stocks In Full Breakout Mode

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animal

Halozyme Issues New Preclinical Data at ASCO: PEGPH20 Boosted T-Cell Access to Tumor Cells in Animals

Halozyme to Advance PEGPH20 Following FDA Meet - Analyst Blog

MLV: We're Reiterating A Buy On Halozyme

Halozyme Therapeutics Spikes Up Following FDA News

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer

Individual Investor Portfolio: Select Sectors And Companies Continue To Beat Market Indices And Peer Groups

Commit To Buy Halozyme Therapeutics At $10, Earn 15.5% Using Options

Insider Trading Alert - GCAP, HALO And ALIM Traded By Insiders

Halozyme Q4 Loss Narrower-than-Expected, Revenues Up - Analyst Blog

See More HALO News...

HALO's Top Competitors

HALO $15.12 (-3.63%)
Current stock: HALO
AMGN $159.44 (-1.65%)
Current stock: AMGN
GILD $102.99 (-2.53%)
Current stock: GILD
BIIB $385.80 (-0.11%)
Current stock: BIIB